TY - JOUR
T1 - Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
AU - McLaughlin, Vallerie V.
AU - Oudiz, Ronald J.
AU - Frost, Adaani
AU - Tapson, Victor F.
AU - Murali, Srinivas
AU - Channick, Richard N.
AU - Badesch, David B.
AU - Barst, Robyn J.
AU - Hsu, Henry H.
AU - Rubin, Lewis J.
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Rationale: Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). Objective: To evaluate the safety and efficacy of adding inhaled iloprost, a prostacyclin analog, to the endothelin receptor antagonist bosentan in patients with PAH. Methods: In a randomized, multicenter, double-blind trial, inhaled iloprost (5 μg) or placebo was added to stable monotherapy with bosentan for 12 wk. Efficacy endpoints included change from baseline in 6-min-walk distance (6-MWD), modified New York Heart Association (NYHA) functional class, hemodynamic parameters, and time to clinical worsening. Measurements and Main Results: A total of 67 patients with PAH (55% idiopathic PAH, 45% associated PAH, 94% NYHA class III, and mean baseline 6-MWD of 335 m) were randomized. At Week 12, patients receiving iloprost had a mean increase in 6-MWD of 30 m (p = 0.001); placebo patients had a mean 6-MWD increase of 4 m (p = 0.69), with a placebo-adjusted difference of +26 m (p = 0.051). NYHA status improved by one class in 34% of iloprost versus 6% of placebo patients (p = 0.002). Iloprost delayed the time to clinical worsening (p = 0.0219). Improvements were noted in postinhalation placebo-adjusted change in mean pulmonary artery pressure (-8 mm Hg; p < 0.001) and pulmonary vascular resistance (-254 dyn·s· cm-5; p < 0.001). Combination therapy was well tolerated. Conclusions: Within the limitations of a relatively small sample size, results of this study demonstrate that the addition of inhaled iloprost in patients with PAH with reduced exercise capacity on bosentan monotherapy is safe and efficacious.
AB - Rationale: Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). Objective: To evaluate the safety and efficacy of adding inhaled iloprost, a prostacyclin analog, to the endothelin receptor antagonist bosentan in patients with PAH. Methods: In a randomized, multicenter, double-blind trial, inhaled iloprost (5 μg) or placebo was added to stable monotherapy with bosentan for 12 wk. Efficacy endpoints included change from baseline in 6-min-walk distance (6-MWD), modified New York Heart Association (NYHA) functional class, hemodynamic parameters, and time to clinical worsening. Measurements and Main Results: A total of 67 patients with PAH (55% idiopathic PAH, 45% associated PAH, 94% NYHA class III, and mean baseline 6-MWD of 335 m) were randomized. At Week 12, patients receiving iloprost had a mean increase in 6-MWD of 30 m (p = 0.001); placebo patients had a mean 6-MWD increase of 4 m (p = 0.69), with a placebo-adjusted difference of +26 m (p = 0.051). NYHA status improved by one class in 34% of iloprost versus 6% of placebo patients (p = 0.002). Iloprost delayed the time to clinical worsening (p = 0.0219). Improvements were noted in postinhalation placebo-adjusted change in mean pulmonary artery pressure (-8 mm Hg; p < 0.001) and pulmonary vascular resistance (-254 dyn·s· cm-5; p < 0.001). Combination therapy was well tolerated. Conclusions: Within the limitations of a relatively small sample size, results of this study demonstrate that the addition of inhaled iloprost in patients with PAH with reduced exercise capacity on bosentan monotherapy is safe and efficacious.
KW - Bosentan
KW - Iloprost
KW - Pulmonary arterial hypertension
UR - http://www.scopus.com/inward/record.url?scp=33845526777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845526777&partnerID=8YFLogxK
U2 - 10.1164/rccm.200603-358OC
DO - 10.1164/rccm.200603-358OC
M3 - Article
C2 - 16946127
AN - SCOPUS:33845526777
SN - 1073-449X
VL - 174
SP - 1257
EP - 1263
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 11
ER -